Table 1. Patients' characteristics and surgical information (n=40).
| Baseline characteristics | Values | |
|---|---|---|
| Median age (yr) | 63 (43–77) | |
| Comorbidity | ||
| Hypertension | 12 (30.0) | |
| Diabetes | 5 (12.5) | |
| Hypothyroidism | 4 (10.0) | |
| Other | 4 (10.0) | |
| Histologic type | ||
| Serous | 37 (92.5) | |
| Clear cell | 2 (5.0) | |
| Carcinosarcoma | 1 (2.5) | |
| FIGO stage | ||
| III | 17 (42.5) | |
| IV | 23 (57.5) | |
| ASA score | ||
| 2 | 16 (40.0) | |
| 3 | 24 (60.0) | |
| Median CA-125 level (U/mL) | 1,691.7 (75.2–17,303.1) | |
| Cycles of NAC | 3 (1–4) | |
| Fagotti score at diagnostic laparoscopy | 10 (8–14) | |
| Surgical procedure | ||
| Diaphragmatic peritonectomy | 24 (60.0) | |
| Splenectomy | 10 (25.0) | |
| Bowel resection | 11 (27.5) | |
| Pelvic and paraaortic lymph-node dissection | 28 (70.0) | |
| Residual disease (cm) | ||
| Not gross | 17 (42.5) | |
| ≤0.5 | 20 (50.0) | |
| ≤1.0 | 3 (7.5) | |
| >1.0 | 0 (0) | |
| Mean operative time (min) | 509.0 (129–915) | |
| Blood transfusion during surgery | 29 (72.5) | |
| Median time interval between surgery and the start of adjuvant chemotherapy | 21 (8–50) | |
Values are presented as median (range) or number of patients (%).
ASA, American Society of Anesthesiologists; CA, cancer antigen; FIGO, International Federation of Gynecology and Obstetrics; NAC, neoadjuvant chemotherapy.